Abstract Survival of motor neuron 2 (SMN2) is a modifier gene for spinal muscular atrophy (SMA), a neurodegenerative disease caused by insufficient SMN protein mostly due to SMN1 defect. SMN2 is nearly identical to SMN1 but unfortunately only able to produce a small amount of SMN protein due to exon 7 skipping. The exon 7-containing SMN2 transcript (SMN2_E7?) can be increased by a dietary compound, curcumin, but the involved molecular changes are not clear. Here we have found that in fibroblast cells of a SMA type II patient, curcumin enhanced the inclusion of SMN2 exon 7. Examination of the potential splicing factors showed that curcumin specifically increased the protein and transcript levels of SRSF1. The increased SRSF1 protein was mainly nuclear and hyperphosphorylated. Interestingly, the curcumin effects on the SMN2 and SRSF1 transcripts were inhibited by a protein deacetylase inhibitor, trichostatin A. Moreover, in support of its role in the SMN2 splicing, knocking down SRSF1 reduced the inclusion of SMN2 exon 7. Thus, curcumin appears to have multiple effects on the SMN2 transcript and its splicing regulators, including the change of alternative splicing and transcript/ protein level as well as phosphorylation. Protein deacetylases and phosphatases are likely involved in these effects. Interestingly, the effects all seem to favor production of the SMN2_E7? transcript in SMA patient cells.
Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder with an estimated incidence of 1 in 6000 live births, representing the primary genetic cause of infant mortality (Monani 2005; Burghes and Beattie 2009 ). The disease is characterized by degeneration of a-motor neurons in the anterior horn of the spinal cord and by consequent skeletal muscle atrophy (Monani 2005; Burghes and Beattie 2009) . More than 96 % of SMA patients have insufficient amount of the survival of motor neuron (SMN) protein due to the homozygous deletion of the SMN1 gene (Coovert et al. 1997; Lefebvre et al. 1995) . Interestingly, a paralogous human gene SMN2 encodes the same but only a small amount of the SMN protein (Lefebvre et al. 1995; Kashima et al. 2007 ), due to its various extents of exon 7 skipping in different cells/tissues (Burnett et al. 2009; Lorson et al. 1998) . Of the many SMNElectronic supplementary material The online version of this article (doi:10.1007/s12263-015-0486-y) contains supplementary material, which is available to authorized users. deficient tissues (Zhang et al. 2008) , spinal cord is the most affected in terms of function and survival (Burghes and Beattie 2009; Chen et al. 2008) .
A C6-to-T transition in exon 7 of the SMN2 gene is shown to contribute to the skipping, by disrupting the binding of a splicing activator SRSF1 (serine-/arginine-rich splicing factor 1) (Cartegni and Krainer 2002; Cartegni et al. 2006 ) and (or) promoting the binding of a splicing repressor hnRNP A1 (heterogeneous nuclear ribonucleoprotein A1) (Kashima et al. 2007; Kashima and Manley 2003) , in splicing reporter assays. Another splicing repressor of the SMN2 exon 7 is SAM68 (Src-associated substrate in Mitosis of 68 kDa) (Pedrotti et al. 2010 ). There are likely more factors involved in the regulation, as suggested by the effects of anti-sense oligonucleotides targeting other regions of the SMN2 pre-mRNA (Singh et al. 2006; Hua et al. 2010) .
Though the expression of SMN2 is not sufficient to compensate for the homozygous loss of SMN1 (Lefebvre et al. 1995) , multiple copies of SMN2 increase SMN protein level and inversely correlate with disease severity in SMA patients and transgenic mice (Hsieh-Li et al. 2000; Monani et al. 2000; Wirth et al. 2006; Swoboda et al. 2005) . Thus, as a modifier gene for SMA, the alternative splicing of SMN2 exon 7 provides a promising target for SMA therapy (Hua et al. 2010) .
Curcumin is a dietary polyphenol compound enriched in the turmeric root. It has been used in clinical trials of numerous human diseases (Gupta et al. 2013; Darvesh et al. 2012) , likely involving its regulation of multiple targets including histone acetyl-transferase (Shishodia 2013; Shishodia et al. 2007 ). It has also been reported to increase the SMN2_E7? transcript and SMN protein in fibroblast cells from a patient with SMA type I (Sakla and Lorson 2008) ; however, the underlying molecular changes have been unclear. For the treatment of human diseases (Gupta et al. 2012) , it is necessary to identify its potential targets and effects.
In this study, we report that curcumin increases expression of the SMN2_E7? transcript and SMN protein in fibroblast cells from a SMA patient with multiple effects: enhancing SMN2 exon 7 inclusion, increasing transcript/protein level, and phosphorylation of the splicing activator SRSF1. These effects likely involve deacetylases and phosphatases.
Results
Curcumin increases the SMN protein and the proportion of SMN2_E71 transcript in fibroblast cells form a patient with SMA type II To investigate potential curcumin effect on the expression of SMN protein and the usage of SMN2 exon 7, a SMA dermal fibroblast cell line (BJ301J) was established by using the skin biopsy of a patient (SMA type II, 6-month, male), who is deficient in both copies of the SMN1 gene but contains three copies of SMN2 (Figs. S1 and S2). In our initial tests, 15-25 lM of curcumin increased the SMN2_E7? transcript, but only 25 lM was sufficient to upregulate the SMN protein level. We thus used 25 lM of curcumin on these cells in the following experiments.
At 25 lM, curcumin efficiently increased the SMN protein level by 1.8-folds after 48 h of treatment in the BJ301J cells (Fig. 1a, b , p \ 0.001). Consistent with the protein upregulation, the percentage of the SMN2_E7? transcript was significantly increased from 45.0 % (±2.2 %, n = 3, calculated at molar level, same as in the following) at 0 h to 59.1 % (±2.3 %, n = 3, p \ 0.01) at 24 h, and further to 65.1 % (±0.9 %, n = 3, p \ 0.001) at 48 h (Fig. 1c, d ) upon curcumin treatment.
Curcumin-induced increase in the SMN2_E71 variant is inhibited by trichostatin A, a deacetylase inhibitor
Curcumin inhibits the histone acetyl-transferase (HAT) and phosphatases 2A and 5 (Balasubramanyam et al. 2004; Han et al. 2012) . To examine whether protein deacetylation or phosphorylation is involved in the increase in SMN2_E7? by curcumin, the BJ301J cells were pretreated for 2 h with trichostatin A (TSA, 1 lM), an inhibitor of deacetylase of histone and non-histone proteins (Dokmanovic et al. 2007; Glozak and Seto 2007) , or okadaic acid (OA, 10 nM), an inhibitor of the protein Ser/Thr phosphatases PP1 and PP2A (Bialojan and Takai 1988) , respectively, followed by curcumin treatment for 24 h (Fig. 2a) . TSA but not OA pretreatment prevented the increase in the percentage of the SMN2_E7? transcripts by curcumin in RT-PCR analysis (lane 3 vs. lane 2). Thus, curcumin-induced increase in the SMN2_E7? variant is specifically inhibited by the protein deacetylase inhibitor TSA, suggesting that a deacetylation step is required for the regulation.
SRSF1 is specifically increased at both protein and transcript levels by curcumin
To identify the curcumin-regulated trans-acting factors, we examined several of them in the control of exon 7 usage, including SRSF1, hnRNP A1, and SAM68. The total protein level of SRSF1 was increased after 24-h treatment with curcumin in western blot analysis (Fig. 3a) . The increase can also be clearly seen in the nucleus by immunostaining (Fig. 3b) . In contrast, the SAM68 protein was reduced (Fig. 3a, b) . Consistent with their protein changes, the level of SRSF1 and SAM68 mRNA transcripts was significantly increased by 144.6 % (±21.8 %, n = 3, p \ 0.01) or reduced by 19.8 % (±1.2 %, n = 3, p \ 0.001), respectively (Fig. 3c) . HnRNP A1 did not change significantly in either protein level or transcript level (Fig. 3) . Thus, SRSF1 and SAM68 are specifically regulated by curcumin at both protein and transcript levels.
Curcumin increases the hyperphosphorylated isoform of SRSF1 in the nucleus
To further characterize the changes of the splicing factors regulated by curcumin, we examined the phosphorylation status of nuclear SRSF1, which is required for SRSF1 nuclear/speckle localization and recruitment to nascent transcripts (Ngo et al. 2005) . For this purpose, we used cleanly separated cytoplasmic and nuclear proteins, as indicated by the exclusive presence of GAPDH and hnRNP F/H in the respective fractions (Fig. 4a, left panel) . Analysis of these fractions indicated that the increase in total SRSF1 protein was mainly in the nucleus (right panel). Moreover, of the two bands below 35 kD recognized by the SRSF1 antibody (clone 96), it was the upper band at about 34 kD that became much stronger in the nucleus upon curcumin treatment. Thus, curcumin increases the level of a specific nuclear SRSF1 protein isoform.
The lower band of SRSF1 at about 32 kD is clearly visible in the presence of 4 mM of NaF in the protein lysates (Fig. 4a) ; however, it was not detectable when a higher concentration of NaF (10 mM) was used ( Fig. 4b) , suggesting that it is a less phosphorylated isoform. To explore the phosphorylation status of the two SRSF1 isoforms upon curcumin treatment, we immunoprecipitated (IP) the SRSF1 protein from the cytoplasmic fraction, followed by treatment with calf intestinal alkaline phosphatase (CIAP) (Fig. 4c) . Upon CIAP treatment, the *34-kD SRSF1 disappeared, compared to the untreated cell lysate or SRSF1 precipitate in western blot of the IP samples (lane 2 vs. lanes 1 and 3). Simultaneously, an extra much lower band appeared at about 30 kD in the same CIAP-treated sample (lane 2). Thus, it is likely that the *34-kD SRSF1 increased by curcumin is a hyperphosphorylated isoform.
Curcumin-induced increase in SRSF1 is inhibited by trichostatin A
To see whether TSA also has effect on the curcumin regulation of SRSF1, we examined its protein and transcript levels in the BJ301J cells pretreated with deacetylase inhibitor TSA (2 h) followed by treatment with curcumin (24 h). SRSF1 protein was again increased in the nuclear fraction by curcumin addition (Fig. 5a ). By contrast, curcumin-induced increase in the nuclear SRSF1 protein was reduced by TSA pretreatment (Fig. 5a ). Accompanying the protein change, upregulation of the SRSF1 transcript (244.6 ± 21.9 %, n = 3, p \ 0.01, Fig. 5b ) by curcumin in comparison with DMSO was abolished upon pretreatment by TSA (117.0 ± 11.4 %, n = 3, p \ 0.001, Fig. 5b ). Therefore, a protein deacetylation step is likely also required for the curcumin-induced increase in SRSF1 transcript/protein as well.
SRSF1 knockdown reduces the inclusion of SMN2 exon 7
To determine the role of SRSF1 in SMN2 exon 7 usage and in the curcumin effect, we carried out lentiviral vectormediated shRNA knockdown of SRSF1 in the BJ301J cells (Fig. 6a) . In mock-treated or scrambled shRNA-expressing cells, the molar percentage of the SMN2_E7? variant was increased from about 43.7-56.1 % by curcumin (Fig. 6b , upper panel, lanes 1-4). Upon SRSF1 knockdown, the SMN2_E7? transcript level was reduced significantly to 32.5 % (±1.4 %, n = 3, p \ 0.01, lane 5 vs. lanes 1 and 3). Treatment with curcumin was still able to increase the level but merely to 44.0 % (±1.9 %, n = 3, lane 6), significantly lower than that in control samples (p \ 0.001, lanes 2 and 4). In contrast, hnRNP A1 knockdown did not change the basal level of the SMN2 splice variants (lanes 7-8). Thus, SRSF1 knockdown reduces the percentage of exon 7 inclusion in the SMA patient cells, supporting SRSF1 as a weak splicing activator of SMN2 exon 7. However, it is not essential for the curcumin enhancement of exon 7 inclusion, suggesting the existence of more factors involved in the curcumin effect. Taken together, these data indicate that the dietary compound curcumin has multiple effects on SMN2 and its splicing regulators to promote the expression of the SMN2_E7? transcripts in SMA fibroblast cells. These effects likely involve protein deacetylation and/or phosphorylation.
Discussion
SMA patient fibroblast cells from a type I patient have been used to investigate the regulation of SMN2 pre-mRNA splicing by small compounds (Sakla and Lorson 2008; Dayangac-Erden et al. 2011) . In this study, the BJ301J cells were derived from a patient (male, 9 months old) with SMA type II. They are homozygously deleted of the SMN1 but have three copies of the SMN2 gene (Fig. S1) , with one more copy of SMN2 than the previously reported GM3813 cells (from a SMA type I, 3-year old male) (Sakla and Lorson 2008; Dayangac-Erden et al. 2011) . In both types of cells, the fold increases in the percentages of SMN2_E7? transcripts are similar (about 1.5-fold) upon 24-h treatment with 25 lM of curcumin. This similar change implies that the curcumin targets in promoting the production of fulllength SMN2 transcript might be the same in different sources and types of SMA cells.
Curcumin has pleiotropic effects on a number of targets in cells (Shishodia 2013; Shishodia et al. 2007 ), particularly the histone acetyltransferase p300-/CREB-binding protein (p300/CBP) (Balasubramanyam et al. 2004) . Of the different effects by curcumin, changes in splicing and transcript levels (Figs. 1, 2, 3) could be contributed by its inhibition of p300/CBP and protein/histone acetylation (Balasubramanyam et al. 2004 ). This is supported by the inhibition of these curcumin effects by the histone deacetylase (HDAC) inhibitor TSA (Figs. 2, 5 ). Particularly for SRSF1, we have shown that curcumin inhibits the histone acetylation/transcription of factors involved in the nonsense-mediated decay (NMD) pathway, consequently increasing the level of NMD-targeted SRSF1 variant transcripts in cells (Feng et al. 2015) . The HDAC inhibitor may also increase the processivity of RNA Polymerase II and reduce co-transcriptional association of splicing l a n e s ** * Fig. 2 Curcumin-induced increase in the SMN2_E7? variant is inhibited by trichostatin A. a RT-PCR analysis of the SMN2 variants (E7? and E7-) in the cytoplasm of the BJ301J fibroblast cells upon 2 h of pretreatment with TSA or OA followed by 24-h addition of curcumin. GAPDH RNA loading control. b A bar graph represents the molar percentages of exon 7-containing SMN2 transcript (SMN2_E7? mol%) are calculated as the molar intensity of the 364-bp product (SMN2_E7?) relative to the total of the 364-and 310-bp (SMN2_E7-) products (mean ± SD, n = 3) in each lane of the gel in a. *p \ 0.05, **p \ 0.01, comparison between the indicated samples regulators with certain alternative exons (Hnilicova et al. 2011) , which may counteract the curcumin-enhanced exon 7 usage.
The curcumin effect on SMN2 splicing and SRSF1 phosphorylation (Figs. 1, 2, 4) may also involve the inhibition of phosphatases such as PP1 and PP2A. PP1 binds to the beta-4 sheet of the SRSF1 RNA recognition motif (RRM1) domain, thus dephosphorylating the splicing factor (Novoyatleva et al. 2008 ). PP1 inhibition promotes SMN2 exon 7 inclusion in fibroblast cells of SMA patients and spinal cord of SMA mice (Novoyatleva et al. 2008 ). Both PP1 and PP2A can be inhibited by okadaic acid (OA). PP2A activity can also be inhibited by curcumin (Han et al. 2012) . However, in our experiments, OA pretreatment did not change the curcumin effect on exon 7 inclusion in cells (Fig. 2) . A reasonable explanation is that curcumin and OA have overlapping effects on the phosphatases and thus the phosphorylation of the splicing factors for SMN2 exon 7 usage.
In the immunoprecipitation experiment (Fig. 4c) , we were not able to efficiently immunoprecipitate the nuclear SRSF1 protein, likely due to occupation of its RRM1 domain by phosphatases (Novoyatleva et al. 2008) , which is part of the N-terminal antigen targeted by the SRSF1 antibody.
In summary, we have observed multiple effects of curcumin on the expression of genes involved in the production of the full-length SMN2 protein. These effects on gene transcription/splicing and protein phosphorylation could be contributed by the inhibitory effect of curcumin on the histone acetyl-transferase p300/CBP and protein phosphatases. These two targets are likely important for the overall beneficial effects for producing the full-length SMN2 protein. RT-PCR analysis of the splicing factors (mean ± SD, n = 3) upon 24 h of treatment with DMSO or curcumin. Each transcript was normalized to that of GAPDH and then to that of the DMSO-treated sample, which is set as 100 %. **p \ 0.01, ***p \ 0.001, compared to DMSO-treated samples
Materials and methods

Cell culture and treatment
Human fibroblast cells (BJ301J) were derived from a type II SMA patient (male, 9 months old) with three copies of the SMN2 gene and maintained in Dulbecco's modified Eagle's medium supplemented with 10 % fetal bovine serum, 2 mM glutamine, and 1 % penicillinstreptomycin solution (Invitrogen) at 37°C in a humidified atmosphere containing 5 % CO 2 . Cells were treated with DMSO or 25 lM of curcumin (Sigma-Aldrich) for 0, 24, or 48 h. In the assay of inhibitors on transcript of SMN2 or SRSF1, cells were pretreated with each inhibitor for 2 h followed by 24-h addition of DMSO or 25 lM of curcumin. protein isoforms in total lysates supplemented with different concentrations of NaF. The lower band of SRSF1 upon curcumin treatment is relatively much weaker than that in DMSO-treated cell lysate and not detected when a higher concentration of NaF (10 mM) was used. b-ACTIN protein loading control. c Western blot analysis of IP cytoplasmic SRSF1 protein in curcumin-treated BJ301J fibroblast cells with or without CIAP treatment. Black-filled and unfilled triangles indicate the hyperphosphorylated and the dephosphorylated isoforms of SRSF1, respectively. *Non-specific bands Knockdown of splicing factors using lentiviral vector-mediated transduction Lentiviral particles were prepared using the shRNA plasmids pGIPZ-shSRSF1 (Open Biosystems, RMM4431-99938975, 5 0 -TCG AGA TCG AGA TCT TCC A-3 0 ), pGIPZ-shhnRNPA1 (5 0 -GTG TAA AGC ATT CCA ACG A-3 0 ), and pGIPZ-scrambled (5 0 -TAG TGA AGC CAC AGA ATA T-3 0 ) according to our previous procedures (Liu et al. 2012; Yu et al. 2009 ). Cells were treated with DMSO or curcumin 7 days after transduction. The silencing effects were confirmed by RT-PCR and immunoblotting.
Reverse transcription polymerase chain reaction
Cytoplasmic RNA was fractionated according to our previous procedure (Feng et al. 2015; Ma et al. 2007 ) and extracted using the GenElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich). One microgram of cytoplasmic RNA was included in a 10 ll reverse transcription reaction. PCR reactions were carried out for 26-30 cycles. The sequences (5 0 -3 0 ) of the primer pairs were as follows, with the forward primer listed first followed by the reverse primer for each gene. AAA GC, TAT CTT CTA TAA CGC TTC ACA TTC CAG; SRSF1: CCT CCA GAC ATC CGA ACC AAG, TGC TAC GGC TTC TGC TAC GAC; hnRNP A1: GTC TAA GTC AGA GTC TCC TAA AGA GCC, TCT CAT TAC CAC ACA GTC CGT G; SAM68: GCT GAC GGC AGA AAT TGA GAA G, TTG ACA GGT ATC AGC ACT CGC TC; GAPDH: GTC AAC GGA TTT GGT CGT ATT G, AAC CAT GTA GTT GAG GTC AAT GAA G. PCR products were resolved in 2-3 % agarose gels containing 0.5 lg/ml ethidium bromide. The gels presented in figures are inverted digital images. The abundance of the SMN2_E7? splice variants is expressed as molar percentages relative to the total of the SMN2 variants (E7? and E7-).
Western blotting
Cells were rinsed three times with ice-cold PBS, harvested using cell scrapers, pelleted by centrifugation at 14,000 rpm for 30 s at 4°C, and lysed in RIPA buffer (containing 2 mM PMSF, 2 mM Na 3 VO 4 and 10 mM NaF) (Feng et al. 2015) . Protein was quantified using the Bradford method, and samples were run on 10 or 12 % Tris-glycine acrylamide gels and then transferred to polyvinylidene fluoride membranes. The membranes were blocked in 5 % dry milk and probed with the following mouse antibodies, which were all purchased from SantaCruz Biotechnology unless otherwise indicated: anti-SMN (H-7, 1:400), anti-SRSF1 (clone 96, 1:500), anti-hnRNP A1 (9H10, 1:1000), anti-SAM68 (7-1, 1:250), anti-nucleolin (H-6, 1:1000), anti-b-actin (C4, 1:1000), and anti-GAPDH (Sigma, 1G5, 1:2000) . After incubation with peroxidase-conjugated goat anti-mouse immunoglobulin M or G secondary antibodies (Sigma-Aldrich, 1:2000), proteins were visualized using enhanced chemiluminescence (GE Healthcare). Densitometry of the resulting bands was analyzed by Image J (developed by the U.S. National Institutes of Health and available at http://rsb.info.nih.gov/ ij/).
Immunostaining BJ301J fibroblast cells were plated over the slides in sixwell plates, treated with DMSO or curcumin for 24 h, rinsed twice in ice-cold phosphate-buffered saline (PBS) with 1 % BSA, fixed with 4 % paraformaldehyde (PFA) for 15 min and then permeabilized with 0.2 % Triton X-100 for 10 min at room temperature. The fixed cells were incubated overnight at 4°C with mouse monoclonal antibodies anti-SRSF1, anti-hnRNP A1, and anti-Sam68, respectively. The primary antibodies were diluted at 1:100 in TBS (20 mM TrisCl, 500 mM NaCl) containing 1 % BSA. Cells were rinsed twice with TBS and incubated with goat anti-mouse fluorescent secondary antibody (conjugated with FITC, 1:1000) in the dark for 1 h at room temperature. Cell nuclei were counterstained with DAPI (1:6000). The stained cells were mounted with mounting media (Sigma-Aldrich). Images were taken at 1009 magnification with an Olympus microscope.
Fractionation of nuclear and cytoplasmic proteins
BJ301J fibroblast cells were rinsed with ice-cold PBS three times in the dishes then harvested in 1 ml of ice-cold PBS using rubber scrapers. Cell pellets were collected into 1.5-ml tubes by centrifuging at 14,000 rpm for 30 s and then resuspended in ice-cold NP-40 buffer supplemented with 2 mM PMSF, 2 mM Na 3 VO 4 and 10 mM NaF. After centrifugation at 14,000 rpm for 2 min, the supernatant was used as cytoplasmic fraction by additional centrifugation at 14,000 rpm through 24 % (w/v) sucrose cushion, the nuclear pellets were washed twice using 1 ml of icecold NP-40 buffer followed by resuspension in RIPA buffer supplemented with 2 mM PMSF, 2 mM Na 3 VO 4 and 10 mM NaF, then used as nuclear fraction after sonication.
Immunoprecipitaion and phosphatase assay BJ301J fibroblast cells were rinsed with cold PBS for three times. The cytoplasmic and nuclear lysates were prepared according to the protocol described in the section of ''Cytoplasm and nuclei fractionation.'' Protein G beads were washed with cold PBS for five times, then packed with 2 lg of anti-SRSF1 antibody and incubated at 4°C under rotary agitation for 4 h. After washing with cold PBS, the packed beads were incubated overnight with lysates at 4°C. When the incubation time was over, the supernatant was removed by centrifugation, and the beads were washed in lysis buffer three times for further analysis.
The precipitations were suspended in 19 reaction buffer with 10 units of CIAP and incubated at 37°C for 60 min. After that, the suspensions were mixed with 69 SDS loading buffer, heated at 95°C for 5 min to denature the proteins, and separated them from the protein G beads, and the supernatants were used for western blotting analysis.
Statistical analysis
Data were analyzed by two-tailed Student's t test. A p value \0.05 was considered significant. 
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